Yuan-Ming Pan et al., indicated that STAT3 activation promotes EZH2 upregulation, which correlates with advanced TNM stage and poor prognosis in GC, suggesting STAT3 inhibition as a novel therapeutic strategy (Pan et al., 2016). This evidence concerns the gene EZH2 and gastric cancer.